4.4 Review

Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy

期刊

KIDNEY & BLOOD PRESSURE RESEARCH
卷 31, 期 1, 页码 29-37

出版社

KARGER
DOI: 10.1159/000112922

关键词

IgA nephropathy; glycosylation; immune complexes; glycosyltransferases

资金

  1. NCRR NIH HHS [M01 RR000032, M01 RR00032] Funding Source: Medline
  2. NIDDK NIH HHS [DK61525, R01 DK078244, DK71802, R01 DK071802, P01 DK061525, R56 DK078244, DK78244] Funding Source: Medline
  3. NIGMS NIH HHS [R01 GM098539] Funding Source: Medline
  4. NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK078244, R01DK078244, P01DK061525, R01DK071802] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098539] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Studies of the properties of immune complexes ( IC)in the circulation, urine, and mesangium of IgA nephropathy (IgAN) patients have provided data relevant to the pathogenesis of this disease. IC contain predominantly polymeric IgA1 molecules which are deficient in galactose (Gal) residues on O-linked glycan chains in the hinge region (HR) of their heavy (H) chains. As a result of this aberrancy, a novel antigenic determinant(s) involving N-acetylgalactosamine (GalNAc) and perhaps sialic acid (SA) of O-linked glycans is generated and recognized by naturally occurring GalNAc-specific antibodies. Thus, IC in IgAN consist of Gal-deficient IgA1 molecules as an antigen, and GalNAc-specific IgG and/or IgA1 as an antibody. IgG antibodies to Gal-deficient IgA1 are probably induced by cross-reactive microbial antigens; they are present at variable levels not only in humans with or without IgAN but also in many phylogenetically diverse vertebrate species. Incubation of human mesangial cells with IC from sera of IgAN patients indicated that stimulation of cellular proliferative activity was restricted to the large (> 800 kDa) complexes. These findings suggest that experimental approaches that prevent the formation of large Gal-deficient IgA1-IgG IC may be applied ultimately in an immunologically mediated therapy. Copyright (C) 2008 S. Karger AG, Basel.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据